Skip to content
← All treatment topics

TREATMENT READING

Endometrial Cancer

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

37 sections
  1. Treatment Option Overview for Endometrial Cancer
  2. Treatment of Stage I and Stage II Endometrial Cancer
  3. Treatment Options for Stage I and Stage II Endometrial Cancer
  4. Surgery
  5. Surgery with or without lymph node sampling
  6. Postoperative vaginal brachytherapy
  7. Postoperative radiation therapy
  8. Radiation therapy alone
  9. Treatment of Stage III, Stage IV, and Recurrent Endometrial Cancer
  10. Treatment Options for Stage III, Stage IV, and Recurrent Endometrial Cancer
  11. Surgery followed by chemotherapy or radiation therapy
  12. Chemotherapy and radiation therapy
  13. Hormone therapy
  14. Biological therapy
  15. Immunotherapy
  16. Clinical trials
  17. Certain factors affect prognosis (chance of recovery) and treatment options.
  18. Endometrial cancer may be grouped for treatment as follows:
  19. Low-risk endometrial cancer
  20. High-risk endometrial cancer
  21. Endometrial cancer can recur (come back) after it has been treated.
  22. Treatment Option Overview
  23. Key Points
  24. There are different types of treatment for patients with endometrial cancer.
  25. Five types of standard treatment are used:
  26. Surgery
  27. Radiation therapy
  28. Chemotherapy
  29. Hormone therapy
  30. Targeted therapy
  31. New types of treatment are being tested in clinical trials.
  32. Treatment for endometrial cancer may cause side effects.
  33. Patients may want to think about taking part in a clinical trial.
  34. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  35. Follow-up tests may be needed.
  36. Treatment of Stage I and Stage II Endometrial Cancer
  37. Treatment of Stage III, Stage IV, and Recurrent Endometrial Cancer

Health professional

Treatment Option Overview for Endometrial Cancer

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

The degree of tumor differentiation has an important effect on the natural history of this disease and on treatment selection.

Patients with endometrial cancer who have localized disease are usually cured. Best results are obtained with one of two standard treatments:

Hysterectomy with bilateral salpingo-oophorectomy.

Hysterectomy with bilateral salpingo-oophorectomy and adjuvant radiation therapy (when deep invasion of the myometrial muscle [more than 50% of the myometrium] or grade 3 tumor with myometrial invasion is present).

Patients with regional and distant metastases are rarely cured, although they are occasionally responsive to standard hormone therapy.

Progestational agents have been evaluated as adjuvant therapy in several randomized trials. A meta-analysis by the Cochrane group confirms no clinical benefit to adjuvant progestogens in clinical stage I disease.[1][Level of evidence A1]

Sources: 1 · Level of evidence A1

The treatment options for each stage of endometrial cancer are presented in Table 11.

Sources: Table 11

Table 11. Treatment Options for Endometrial Cancer
Stage (FIGO Staging Definitions)Treatment Options
FIGO = Fédération Internationale de Gynécologie et d’Obstétrique.
Stage I and stage II endometrial cancerGrades 1 and 2Surgery with or without lymph node sampling
Postoperative vaginal brachytherapy
Radiation therapy alone
Grade 3 (includes serous, clear cell, and carcinosarcoma)Surgery
Postoperative chemotherapy with or without radiation therapy
Stage III, stage IV, and recurrent endometrial cancerOperable diseaseSurgery followed by chemotherapy or radiation therapy
Inoperable diseaseChemotherapy and radiation therapy
Inoperable disease in which the patient is not a candidate for radiation therapyHormone therapy
Biological therapy
Advanced or recurrent diseaseImmunotherapy
Clinical trials

Sources: Stage (FIGO Staging Definitions) · Surgery with or without lymph node sampling · Postoperative vaginal brachytherapy · Radiation therapy alone · Surgery · Postoperative chemotherapy with or without radiation therapy · Surgery followed by chemotherapy or radiation therapy · Chemotherapy and radiation therapy · Hormone therapy · Biological therapy · Immunotherapy · Clinical trials

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment of Stage I and Stage II Endometrial Cancer

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage I and Stage II Endometrial Cancer

Treatment Options for Stage I and Stage II Endometrial Cancer

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment of stage I and stage II endometrial cancer depends on the grade and histological type.

In the current Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) staging system, stage II describes tumor that invades the cervical stroma; this is equivalent to the prior stage IIB. Almost all randomized trials for early-stage cancer excluded stage IIB patients. As a result, there is a paucity of quality data on which to base clinical decisions for patients with stage II endometrial cancer.

Low-risk histology:

Grades 1 and 2 tumors are considered low-risk unless they have serous or clear cell histologies.

Treatment options for patients with low-risk histological subtypes of stage I endometrial cancer include:

Surgery: Hysterectomy with bilateral salpingo-oophorectomy and possible lymph node dissection.

Sources: Surgery

Postoperative vaginal brachytherapy.

Sources: Postoperative vaginal brachytherapy

Radiation therapy alone.

Sources: Radiation therapy alone

Most patients do well with surgery alone. However, patients with stage I disease who have high-risk histologies are at a greater risk of recurrence and are eligible for adjuvant therapy.

High-risk histology:

Grade 3 tumors of any histology and any serous tumors, clear cell tumors, or carcinosarcomas are considered high-risk.

Treatment options for patients with stage I or stage II endometrial cancer who have high-risk histologies include:

Surgery: Hysterectomy with bilateral salpingo-oophorectomy, with pelvic and para-aortic lymph node dissection.

Sources: Surgery

Postoperative chemotherapy with or without radiation therapy.

Patients with serous or clear cell histologies have higher rates of recurrence than do patients with other stage I or stage II endometrioid carcinomas. Management guidelines are based on the outcomes reported in institutional case series that used a regimen of adjuvant carboplatin plus paclitaxel, and occasionally, radiation therapy for patients with this histological subtype.[1-9]

Sources: 1 · 9

Carcinosarcomas have been evaluated in clinical trials both separately and with other sarcomas because of their prior designation in this group. In a nonrandomized Gynecologic Oncology Group (GOG) study of patients with stage I or II carcinosarcomas, patients who underwent pelvic radiation therapy had a significant reduction in recurrences within the radiation treatment field but no improvement in survival.[10] One nonrandomized study that predominantly included patients with carcinosarcomas appeared to show benefit for adjuvant therapy with cisplatin and doxorubicin.[11]

Sources: 10 · 11

Health professional · Treatment of Stage I and Stage II Endometrial Cancer / Treatment Options for Stage I and Stage II Endometrial Cancer

Surgery

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

If the uterine cervix is involved, patients may consider one or more of the following options:

Standard hysterectomy with bilateral salpingo-oophorectomy, followed by adjuvant radiation therapy.

Radical hysterectomy.

Pelvic and para-aortic lymph node dissection.

Single-institution reviews suggest that radical hysterectomy is more beneficial than standard hysterectomy in cases of cervical involvement of the tumor.[12-14]

Sources: 12 · 14

Health professional · Treatment of Stage I and Stage II Endometrial Cancer / Treatment Options for Stage I and Stage II Endometrial Cancer

Surgery with or without lymph node sampling

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Table 12 highlights the risk of nodal metastasis based on findings at the time of staging surgery:[15]

Sources: Table 12 · 15

Table 12. Risk of Nodal Metastasis in Clinical Stage I Endometrial Cancer
Prognostic GroupPatient CharacteristicsRisk of Nodal Involvement
AGrade 1 tumors involving only endometrium<5%
No evidence of intraperitoneal spread
BGrade 2–3 tumors5%–9% pelvic nodes
Invasion of <50% of myometrium
No intraperitoneal spread4% para-aortic nodes
CDeep muscle invasion20%–60% pelvic nodes
High-grade tumors10%–30% para-aortic nodes
Intraperitoneal spread

For patients in Group A, lymph node dissection has limited utility. Conversely, full pelvic and para-aortic lymph node dissection is important for patients in Group C, given the likelihood of positive findings. The difficulty lies in determining how to manage patients in Group B.

There are several accepted surgical approaches for patients with presumed stage I endometrial cancer, with intermediate risk for lymphatic spread.

Both retrospective and prospective data support stratifying patients with presumed stage I endometrial cancer into two groups based on the following characteristics:

Low risk: Well-differentiated or moderately differentiated tumor and/or depth of myometrial invasion is less than 50% and/or tumor is smaller than 2 cm.

High risk: Poorly differentiated tumor and/or depth of myometrial invasion is 50% or more and/or tumor is 2 cm or larger.

Evidence (lymph node dissection):

In two studies, patients with low-risk cancer had a sufficiently low risk of lymph node metastasis such that lymph node sampling could be omitted. For patients meeting high-risk criteria, a full pelvic and para-aortic lymph node dissection was suggested, given patterns of lymphatic spread.[16,17]

Sources: 16 · 17

An alternative strategy is the use of sentinel lymph node dissection in patients with presumed stage I endometrial cancer.[18] Although this strategy has been widely adopted at various academic centers, a prospective multicenter trial to determine the false-negative rate for this protocol is lacking. For cases in which isolated tumor cells are identified using the sentinel lymph node approach, it is unclear whether treatment is necessary.

Sources: 18

In patients with high-risk histology (serous, clear cell, carcinosarcoma, or undifferentiated tumors), hysterectomy and bilateral salpingo-oophorectomy with pelvic and para-aortic lymph node dissection is the standard approach.

Laparotomy has been the standard surgical approach. However, laparoscopy is now favored because of the improvement in patients' postoperative recovery without significant impact on outcomes.

Evidence (treatment or surgical staging using laparoscopy vs. laparotomy):

For patients with early-stage endometrial cancer, several randomized trials have compared total laparoscopic hysterectomy (TLH) with the standard open procedure, total abdominal hysterectomy (TAH). Feasibility of the laparoscopic approach has been confirmed, but this approach is associated with a longer operative time.[15,19,20] TLH has an improved [15,19] or similar [20] adverse event profile and a shorter hospital stay [15,19,20] than does TAH.

Sources: 15 · 19 · 20 · 15 · 19 · 20 · 15 · 19 · 20

For patients with early-stage endometrial cancer, several randomized trials have compared total laparoscopic hysterectomy (TLH) with the standard open procedure, total abdominal hysterectomy (TAH). Feasibility of the laparoscopic approach has been confirmed, but this approach is associated with a longer operative time.[15,19,20] TLH has an improved [15,19] or similar [20] adverse event profile and a shorter hospital stay [15,19,20] than does TAH.

TLH is associated with less pain and a quicker resumption of daily activities,[20,21] although one study found that most of the gains in quality of life favoring laparoscopy at the 6-week postsurgical period were no longer significant at 6 months.[20,21]

Sources: 20 · 21 · 20 · 21

A GOG trial (GOG-LAP2) randomly assigned 2,616 patients with clinical stages I to IIA disease in a 2:1 ratio to comprehensive surgical staging via laparoscopy or laparotomy.[22][Level of evidence A1]Time to recurrence was the primary end point, with noninferiority defined as a difference in recurrence rate of less than 5.3% between the two groups at 3 years.

Sources: GOG-LAP2 · 22 · Level of evidence A1

A GOG trial (GOG-LAP2) randomly assigned 2,616 patients with clinical stages I to IIA disease in a 2:1 ratio to comprehensive surgical staging via laparoscopy or laparotomy.[22][Level of evidence A1]Time to recurrence was the primary end point, with noninferiority defined as a difference in recurrence rate of less than 5.3% between the two groups at 3 years.

The recurrence rate at 3 years was 10.24% for patients in the laparotomy arm and 11.39% for patients in the laparoscopy arm, with an estimated difference between groups of 1.14% (90% lower bound, -1.278; 95% upper bound, 3.996).

A GOG trial (GOG-LAP2) randomly assigned 2,616 patients with clinical stages I to IIA disease in a 2:1 ratio to comprehensive surgical staging via laparoscopy or laparotomy.[22][Level of evidence A1]Time to recurrence was the primary end point, with noninferiority defined as a difference in recurrence rate of less than 5.3% between the two groups at 3 years. › The recurrence rate at 3 years was 10.24% for patients in the laparotomy arm and 11.39% for patients in the laparoscopy arm, with an estimated difference between groups of 1.14% (90% lower bound, -1.278; 95% upper bound, 3.996).

Although this difference was lower than the prespecified limit, the statistical requirements for noninferiority were not met because of fewer-than-expected recurrences in both groups.

A GOG trial (GOG-LAP2) randomly assigned 2,616 patients with clinical stages I to IIA disease in a 2:1 ratio to comprehensive surgical staging via laparoscopy or laparotomy.[22][Level of evidence A1]Time to recurrence was the primary end point, with noninferiority defined as a difference in recurrence rate of less than 5.3% between the two groups at 3 years.

The 5-year overall survival (OS) rate was 89.8% in both groups.

A Cochrane review of the use of laparoscopic staging included four randomized controlled trials that reported OS and progression-free survival (PFS). Ninety percent of the patients were from the GOG-LAP2 trial.[23][Level of evidence A1]

Sources: 23 · Level of evidence A1

A Cochrane review of the use of laparoscopic staging included four randomized controlled trials that reported OS and progression-free survival (PFS). Ninety percent of the patients were from the GOG-LAP2 trial.[23][Level of evidence A1]

Overall, laparoscopy and laparotomy were associated with similar OS and PFS rates.

Future analyses may determine whether there are subgroups of patients for whom there is a clinically significant decrement when laparoscopic staging is used.[22][Level of evidence B1]

Sources: 22 · Level of evidence B1

Health professional · Treatment of Stage I and Stage II Endometrial Cancer / Treatment Options for Stage I and Stage II Endometrial Cancer

Postoperative vaginal brachytherapy

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Adjuvant radiation therapy reduces the incidence of local and regional recurrence. However, improved survival rates have not been confirmed, and radiation therapy increased toxicity.[24-28] Vaginal cuff brachytherapy is associated with less radiation-related morbidity than is external-beam radiation therapy (EBRT) and has been shown to be equivalent to EBRT in the short term for patients with stage I disease.[29] However, long-term follow up of a randomized trial comparing EBRT plus vaginal brachytherapy (VBT) to VBT alone found decreased OS and increased toxicity in the EBRT plus VBT arm.[30]

Sources: 24 · 28 · 29 · 30

Evidence (VBT):

Results of two randomized trials that used adjuvant radiation therapy in patients with stage I disease did not show improved survival but did show reduced locoregional recurrence (3%–4% in the radiation therapy group vs. 12%–14% in the control group after median follow-up of 5–6 years; P < .001), with an increase in side effects.[27,31,32][Level of evidence B1]

Sources: 27 · 31 · 32 · Level of evidence B1

Results of a study by the Danish Endometrial Cancer Group suggest that the absence of radiation therapy does not improve the survival of patients with stage I intermediate-risk disease (grades 1 and 2 with >50% myometrial invasion or grade 3 with <50% myometrial invasion).[33]

Sources: 33

The PORTEC-2 trial (NCT00411138) randomly assigned patients with stage I endometrial cancer who did not undergo lymph node dissection to undergo VBT or EBRT, with prevention of vaginal recurrence as the primary outcome.[29,34][Level of evidence A1]

Sources: PORTEC-2 · 29 · 34 · Level of evidence A1

The PORTEC-2 trial (NCT00411138) randomly assigned patients with stage I endometrial cancer who did not undergo lymph node dissection to undergo VBT or EBRT, with prevention of vaginal recurrence as the primary outcome.[29,34][Level of evidence A1]

At 5 years, there was no difference in the rates of vaginal recurrence, locoregional recurrence, PFS, or OS (84.8% [95% confidence interval (CI), 79.3%–90.3%] for VBT vs. 79.6% [95% CI, 71.2%–88.0%] for EBRT; P = .57).

The VBT group had significantly fewer gastrointestinal toxic effects and improved quality of life, making VBT the preferred option for adjuvant treatment of patients with stage I disease.

The Norwegian Radium Hospital trial included 568 patients with clinical stage I endometrial cancer between 1968 and 1974 (before FIGO surgical staging was initiated).[30][Level of evidence A1] After hysterectomy and bilateral salpingo-oophorectomy, patients were randomly assigned to receive either EBRT and VBT or VBT alone.

Sources: 30 · Level of evidence A1

The Norwegian Radium Hospital trial included 568 patients with clinical stage I endometrial cancer between 1968 and 1974 (before FIGO surgical staging was initiated).[30][Level of evidence A1] After hysterectomy and bilateral salpingo-oophorectomy, patients were randomly assigned to receive either EBRT and VBT or VBT alone.

An updated report presenting over 20 years of follow-up data showed no difference in OS between the treatment groups. Median OS was 20.5 years in the EBRT/VBT group and 20.48 years in the VBT-alone group (P = .186). In all women, there was an increased risk of secondary cancers after EBRT (hazard ratio [HR], 1.42; 95% CI, 1.01–2.0).

A post hoc subset analysis of women younger than 60 years at the time of trial registration showed increased mortality in the EBRT/VBT arm (HR, 1.36; 95% CI, 1.06–1.76). Further, the risk of secondary cancers doubled in this group (HR, 2.02; 95% CI, 1.3–3.15).

Health professional · Treatment of Stage I and Stage II Endometrial Cancer / Treatment Options for Stage I and Stage II Endometrial Cancer

Postoperative radiation therapy

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

If the cervix is not clinically involved, but extension to the cervix is noted on postoperative pathology, radiation therapy is considered.[22][Level of evidence A1]

Sources: 22 · Level of evidence A1

Health professional · Treatment of Stage I and Stage II Endometrial Cancer / Treatment Options for Stage I and Stage II Endometrial Cancer

Radiation therapy alone

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Patients who have medical contraindications to surgery may be treated with radiation therapy alone, but cure rates may be lower than those attained with surgery.[35-37]

Sources: 35 · 37

Health professional

Treatment of Stage III, Stage IV, and Recurrent Endometrial Cancer

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage III, Stage IV, and Recurrent Endometrial Cancer

Treatment Options for Stage III, Stage IV, and Recurrent Endometrial Cancer

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Treatment options for patients with stage III, stage IV, and recurrent endometrial cancer include:

Surgery followed by chemotherapy or radiation therapy.

Sources: Surgery followed by chemotherapy or radiation therapy

Chemotherapy and radiation therapy.

Sources: Chemotherapy and radiation therapy

Hormone therapy.

Sources: Hormone therapy

Biological therapy.

Sources: Biological therapy

Immunotherapy.

Sources: Immunotherapy

Clinical trials.

Sources: Clinical trials

Treatment of patients with stage IV endometrial cancer is dictated by the site of metastatic disease and symptoms related to disease sites.

Health professional · Treatment of Stage III, Stage IV, and Recurrent Endometrial Cancer / Treatment Options for Stage III, Stage IV, and Recurrent Endometrial Cancer

Surgery followed by chemotherapy or radiation therapy

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

In general, patients with stage III or stage IV endometrial cancer are treated with surgery, followed by chemotherapy, radiation therapy, or both. Observational studies support maximal cytoreductive surgery for patients with stage IV disease, although these conclusions need to be interpreted with care because of the small number of cases and likely selection bias.[1,2]

Sources: 1 · 2

For many years, radiation therapy was the standard adjuvant treatment for patients with endometrial cancer. However, several randomized trials have confirmed improved survival when adjuvant chemotherapy is used instead of radiation therapy.

Doxorubicin was historically the most active anticancer agent used, with useful but temporary responses obtained in as many as 33% of patients with recurrent disease. Paclitaxel, when combined with platinum chemotherapy or when used as a single agent, also has significant anticancer activity.[3]

Sources: 3

Evidence (surgery followed by chemotherapy or radiation therapy):

Several randomized trials by the Gynecologic Oncology Group (GOG) have used doxorubicin because of its known antitumor activity.[4]

Sources: 4

Several randomized trials by the Gynecologic Oncology Group (GOG) have used doxorubicin because of its known antitumor activity.[4]

Adding cisplatin to doxorubicin increased response rates and progression-free survival (PFS) when compared with doxorubicin alone. However, adding cisplatin did not affect overall survival (OS).

A three-drug regimen of doxorubicin, cisplatin, and paclitaxel with granulocyte-colony stimulating factor (G-CSF) was significantly superior to cisplatin and doxorubicin, as shown by the following results:[5,6][Level of evidence B3] Given the toxicity and limited efficacy of these regimens, other treatment options have been widely sought. Several observational studies [7,8] and phase II studies [9-12] suggest clinical activity with the combination of platinum chemotherapy and paclitaxel in patients with endometrial cancer and measurable disease either after primary surgery or at recurrence.

Sources: 5 · 6 · Level of evidence B3 · 7 · 8 · 9 · 12

A three-drug regimen of doxorubicin, cisplatin, and paclitaxel with granulocyte-colony stimulating factor (G-CSF) was significantly superior to cisplatin and doxorubicin, as shown by the following results:[5,6][Level of evidence B3] Given the toxicity and limited efficacy of these regimens, other treatment options have been widely sought. Several observational studies [7,8] and phase II studies [9-12] suggest clinical activity with the combination of platinum chemotherapy and paclitaxel in patients with endometrial cancer and measurable disease either after primary surgery or at recurrence.

Response rate was 57% with the three-drug regimen, compared with 34% with the cisplatin and doxorubicin regimen.

PFS was 8.3 months with the three-drug regimen, compared with 5.3 months with the cisplatin and doxorubicin regimen.

OS was 15.3 months with the three-drug regimen, compared with 12.3 months with the cisplatin and doxorubicin regimen.

The 3-drug regimen was associated with grade 3 peripheral neuropathy in 12% of patients and grade 2 peripheral neuropathy in 27% of patients.

The phase III, randomized, open-label, noninferiority GOG-0209 trial (NCT000063999) compared the combination of paclitaxel, doxorubicin, cisplatin (TAP), and G-CSF with carboplatin and paclitaxel (TC) in 1,381 women.[13]

Sources: GOG-0209 · 13

The phase III, randomized, open-label, noninferiority GOG-0209 trial (NCT000063999) compared the combination of paclitaxel, doxorubicin, cisplatin (TAP), and G-CSF with carboplatin and paclitaxel (TC) in 1,381 women.[13]

The median OS was 37 months for patients in the TC group and 41 months for patients in the TAP group (hazard ratio [HR], 1.002; 90% confidence interval [CI], 0.9–1.12). The median PFS was 13 months for patients in the TC group and 14 months for patients in the TAP group (HR, 1.032; 90% CI, 0.93–1.15).[13]

Sources: 13

These results led to the use of TC as the standard adjuvant treatment for patients with stages III and IV disease.

The use of cisplatin and doxorubicin compared with whole-abdominal radiation therapy was studied in a trial of patients with stage III or IV disease with residual tumors smaller than 2 cm and no parenchymal organ involvement.[14][Level of evidence A1]

Sources: 14 · Level of evidence A1

The use of cisplatin and doxorubicin compared with whole-abdominal radiation therapy was studied in a trial of patients with stage III or IV disease with residual tumors smaller than 2 cm and no parenchymal organ involvement.[14][Level of evidence A1]

Results suggest that cisplatin and doxorubicin improved OS, compared with whole-abdominal radiation therapy (5-year survival rate, 55% for cisplatin and doxorubicin vs. 42% for whole-abdominal radiation; adjusted HR, 0.68; 95% CI, 0.52–0.89; P = .02).

Several trials support combination chemotherapy for patients with stage III, stage IV, and recurrent carcinosarcoma.

Several trials support combination chemotherapy for patients with stage III, stage IV, and recurrent carcinosarcoma.

The GOG-108 trial of ifosfamide, with or without cisplatin, as first-line therapy in patients with measurable advanced or recurrent carcinosarcomas demonstrated a higher response rate (54% vs. 34%) and longer PFS in the combination arm (6 months vs. 4 months), but there was no significant improvement in survival (9 months vs. 8 months).[15][Level of evidence A1]

Sources: 15 · Level of evidence A1

The follow-up GOG-0161 study (NCT00003128) used 3-day ifosfamide regimens (instead of the more-toxic 5-day regimen in the preceding study) for the control and ifosfamide combined with paclitaxel (with G-CSF starting on day 4) for the study arm.[16]

Sources: GOG-0161 · 16

Several trials support combination chemotherapy for patients with stage III, stage IV, and recurrent carcinosarcoma. › The follow-up GOG-0161 study (NCT00003128) used 3-day ifosfamide regimens (instead of the more-toxic 5-day regimen in the preceding study) for the control and ifosfamide combined with paclitaxel (with G-CSF starting on day 4) for the study arm.[16]

The combination regimen produced superior response rates (45% vs. 29%), PFS (8.4 months vs. 5.8 months), and OS (13.5 months vs. 8.4 months). The HR for death also favored the combination regimen (HR, 0.69; 95% CI, 0.49–0.97).[16][Level of evidence A1]

Sources: 16 · Level of evidence A1

In this study, 52% of 179 evaluable patients had recurrent disease, 18% had stage III disease, and 30% had stage IV disease. In addition, there were imbalances between the treatment arms with respect to the sites of disease and the use of prior radiation therapy, and 30 patients were excluded for wrong pathology.

Health professional · Treatment of Stage III, Stage IV, and Recurrent Endometrial Cancer / Treatment Options for Stage III, Stage IV, and Recurrent Endometrial Cancer

Chemotherapy and radiation therapy

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Patients with inoperable disease caused by tumor that extends to the pelvic wall may be treated with a combination of chemotherapy and radiation therapy. The usual approach for radiation therapy is a combination of intracavitary and external-beam radiation therapy (EBRT).[17,18]

Sources: 17 · 18

For patients with localized recurrences (pelvic and para-aortic lymph nodes) or distant metastases in selected sites, radiation therapy may be an effective palliative therapy. Pelvic radiation therapy may be curative in patients with pure vaginal recurrence when no previous radiation therapy has been used.

Health professional · Treatment of Stage III, Stage IV, and Recurrent Endometrial Cancer / Treatment Options for Stage III, Stage IV, and Recurrent Endometrial Cancer

Hormone therapy

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Progesterone and estrogen hormone receptors are commonly found in endometrial carcinoma tissues. Response to hormone therapy is correlated with the presence and level of hormone receptors and the degree of tumor differentiation.[19] Patients with tumors that are positive for estrogen and progesterone receptors respond best to progestin therapy.

Sources: 19

When distant metastases, especially pulmonary metastases, are present, hormonal therapy is indicated. Patients who are not candidates for either surgery or radiation therapy may be treated with progestational agents, the most common hormonal treatment. Progestational agents produce good antitumor responses in 15% to 30% of patients. These responses are associated with significant improvement in survival.[19]

Sources: 19

Standard progestational agents include:[19]

Sources: 19

Hydroxyprogesterone.

Medroxyprogesterone.

Megestrol.

Evidence (progestin therapy):

One study followed 115 patients with advanced endometrial cancer treated with progestins.[20]

Sources: 20

One study followed 115 patients with advanced endometrial cancer treated with progestins.[20]

Responses occurred in 75% of patients (42 of 56) with progesterone receptor–positive tumors.

Responses occurred in 7% of patients (4 of 59) without detectable progesterone receptors.

A receptor-poor status may predict a poor response to progestins and a better response to cytotoxic chemotherapy.[21]

Sources: 21

Other hormonal agents have shown benefit in treating endometrial cancer. Tamoxifen (20 mg bid) yields a 20% response rate in patients who do not respond to standard progesterone therapy.[22]

Sources: 22

Aromatase inhibitors have also been evaluated for the treatment of advanced and recurrent endometrial cancer, although they yield lower response rates than progestational agents.[23]

Sources: 23

Health professional · Treatment of Stage III, Stage IV, and Recurrent Endometrial Cancer / Treatment Options for Stage III, Stage IV, and Recurrent Endometrial Cancer

Biological therapy

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Several biological agents have been evaluated for the treatment of endometrial cancer.

Mammalian target of rapamycin (mTOR) inhibitors.Endometrial cancers often show alterations in the AKT-PI3K pathway, making mTOR inhibitors an attractive choice for clinical study in patients with metastatic or recurrent disease. Phase II studies of single-agent everolimus [24] and ridaforolimus [25,26] have predominantly shown disease stabilization. A phase II study of the combination of everolimus and letrozole showed a 32% response rate.[27][Level of evidence C3]

Sources: 24 · 25 · 26 · 27 · Level of evidence C3

Bevacizumab.

Bevacizumab.

Bevacizumab was used as a single agent in a phase II trial. The overall response rate was 13.5%.[28][Level of evidence C3]

Sources: 28 · Level of evidence C3

Bevacizumab combined with temsirolimus has been used.[29]

Sources: 29

Health professional · Treatment of Stage III, Stage IV, and Recurrent Endometrial Cancer / Treatment Options for Stage III, Stage IV, and Recurrent Endometrial Cancer

Immunotherapy

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

With the published results of The Cancer Genome Atlas, and as more is learned about the molecular drivers of endometrial cancer, the use of immunotherapy has been evaluated for the treatment of advanced and recurrent disease.

Evidence (immunotherapy):

Study 309/KEYNOTE-775 (NCT03517449) was a large, international, multicenter, randomized trial that compared the combination of pembrolizumab (200mg intravenously [IV] every 3 weeks for up to 35 cycles) and lenvatinib (20mg orally daily) with physician's choice of chemotherapy. The study enrolled women with advanced or recurrent endometrial cancer who had disease progression after a platinum-based regimen (measurable disease was required). All histologies except carcinosarcoma and sarcoma were permitted. Patients were stratified by mismatch repair (MMR) status. The two primary end points were PFS and OS.[30]

Sources: Study 309/KEYNOTE-775 · 30

Study 309/KEYNOTE-775 (NCT03517449) was a large, international, multicenter, randomized trial that compared the combination of pembrolizumab (200mg intravenously [IV] every 3 weeks for up to 35 cycles) and lenvatinib (20mg orally daily) with physician's choice of chemotherapy. The study enrolled women with advanced or recurrent endometrial cancer who had disease progression after a platinum-based regimen (measurable disease was required). All histologies except carcinosarcoma and sarcoma were permitted. Patients were stratified by mismatch repair (MMR) status. The two primary end points were PFS and OS.[30]

After a median follow-up of approximately 12 months in both groups, survivals were statistically longer for patients in the pembrolizumab-lenvatinib group. The benefit persisted despite the patients' MMR statuses. Among all patients, the median PFS was 7.3 months for patients who received pembrolizumab and lenvatinib and 3.8 months for patients who received chemotherapy (HR, 0.56; 95% CI, 0.48–0.66; P < .001). The median OS was 18.7 months for patients who received pembrolizumab and lenvatinib and 11.9 months for patients who received chemotherapy (HR, 0.65; 95% CI, 0.55–0.77; P < .001).[30][Level of evidence A1]

Sources: 30 · Level of evidence A1

The most frequent serious side effect in the experimental group was hypertension.

The double-blind placebo-controlled KEYNOTE-868 study (NCT03914612) included 810 patients with advanced (stage III, stage IVA, or stage IVB) or recurrent endometrial cancer.[31] Patients were randomly assigned to receive six cycles of paclitaxel and carboplatin with either pembrolizumab or placebo. Afterwards, patients received up to 14 cycles of maintenance therapy with pembrolizumab or placebo. Patients were stratified according to MMR statuses (proficient [pMMR; n =588] or deficient [dMMR; n = 222]) to investigate if the checkpoint inhibitor, pembrolizumab, was efficacious in patients with dMMR tumors.

Sources: KEYNOTE-868 · 31

The double-blind placebo-controlled KEYNOTE-868 study (NCT03914612) included 810 patients with advanced (stage III, stage IVA, or stage IVB) or recurrent endometrial cancer.[31] Patients were randomly assigned to receive six cycles of paclitaxel and carboplatin with either pembrolizumab or placebo. Afterwards, patients received up to 14 cycles of maintenance therapy with pembrolizumab or placebo. Patients were stratified according to MMR statuses (proficient [pMMR; n =588] or deficient [dMMR; n = 222]) to investigate if the checkpoint inhibitor, pembrolizumab, was efficacious in patients with dMMR tumors.

After a median follow-up of 12.0 months, the 1-year PFS for patients with dMMR tumors was 74% in the pembrolizumab group and 38% in the placebo group (HR, 0.30; 95% CI, 0.19–0.48; P < .001).[31][Level of evidence B1]

Sources: 31 · Level of evidence B1

After a median follow-up of 7.9 months, the median PFS for patients with pMMR tumors was 13.1 months in the pembrolizumab group and 8.7 months in the placebo group (HR, 0.54; 95% CI, 0.41–0.71; P < .001).[31][Level of evidence B1]

Sources: 31 · Level of evidence B1

Regardless of MMR status, pembrolizumab showed significant PFS improvement in patients with advanced or recurrent endometrial cancer.

The phase III randomized KEYNOTE-B21 trial (NCT04634877) included 1,095 patients with newly diagnosed high-risk stage I to stage IVA endometrial cancer (including carcinosarcoma) without evidence of disease postsurgery. All patients received either six cycles of chemotherapy with optional EBRT or four cycles of chemotherapy followed by chemoradiation therapy. Vaginal brachytherapy was allowed in both groups. Patients were randomly assigned to receive either adjuvant pembrolizumab or placebo every 3 weeks for six cycles, then every 6 weeks for six cycles. A total of 66% of patients had stage III or stage IVA disease, 26% had dMMR tumors, and 67% were treated with radiation therapy.[32,33]This study evaluated giving pembrolizumab to patients with positive lymph nodes after surgery who had no other visible evidence of disease. It also evaluated combining radiation therapy and pembrolizumab. Results were significant because they expanded the population of patients who can receive pembrolizumab.

Sources: KEYNOTE-B21 · 32 · 33

The phase III randomized KEYNOTE-B21 trial (NCT04634877) included 1,095 patients with newly diagnosed high-risk stage I to stage IVA endometrial cancer (including carcinosarcoma) without evidence of disease postsurgery. All patients received either six cycles of chemotherapy with optional EBRT or four cycles of chemotherapy followed by chemoradiation therapy. Vaginal brachytherapy was allowed in both groups. Patients were randomly assigned to receive either adjuvant pembrolizumab or placebo every 3 weeks for six cycles, then every 6 weeks for six cycles. A total of 66% of patients had stage III or stage IVA disease, 26% had dMMR tumors, and 67% were treated with radiation therapy.[32,33]This study evaluated giving pembrolizumab to patients with positive lymph nodes after surgery who had no other visible evidence of disease. It also evaluated combining radiation therapy and pembrolizumab. Results were significant because they expanded the population of patients who can receive pembrolizumab.

After a median follow-up of 24 months, the 2-year disease-free survival (DFS) rate was 75% in the pembrolizumab group and 76% in the placebo group (HR, 1.02; 95% CI, 0.79–1.32; P = .57).[33][Level of evidence B1]

Sources: 33 · Level of evidence B1

In the dMMR cohort, the 2-year DFS rate was 92.4% in the pembrolizumab group and 80.2% in the placebo group (HR, 0.31; 95% CI, 0.14–0.69).

No other predetermined subgroup benefitted from adding pembrolizumab.

The RUBY trial (NCT03981796) was a large multicenter trial in women with Fédération Internationale de Gynécologie et d’Obstétrique stage III, IV, or recurrent endometrial cancer of all histologies not amenable to curative therapy. Unlike the Study 309/KEYNOTE-775 trial, some patients without measurable disease qualified for inclusion. Women were randomly assigned to receive TC with or without dostarlimab (500 mg IV) every 3 weeks for six cycles followed by maintenance dostarlimab (1,000 mg IV every 6 weeks) for up to 3 years. Patients were stratified by MMR status. The primary end point was PFS.[34]

Sources: RUBY · 34

The RUBY trial (NCT03981796) was a large multicenter trial in women with Fédération Internationale de Gynécologie et d’Obstétrique stage III, IV, or recurrent endometrial cancer of all histologies not amenable to curative therapy. Unlike the Study 309/KEYNOTE-775 trial, some patients without measurable disease qualified for inclusion. Women were randomly assigned to receive TC with or without dostarlimab (500 mg IV) every 3 weeks for six cycles followed by maintenance dostarlimab (1,000 mg IV every 6 weeks) for up to 3 years. Patients were stratified by MMR status. The primary end point was PFS.[34]

After a median follow-up of approximately 2 years, the dostarlimab group from the overall population had a 36% lower risk of progression or death (HR, 0.64; 95% CI, 0.51–0.80; P < .001). The dostarlimab group from the dMMR population had a 72% lower risk of progression or death (HR, 0.28; 95% CI, 0.16–0.50; P < .001). Similar benefit was seen in OS (HR, 0.64; 95% CI, 0.46–0.87, P = .0021 for the overall population; HR, 0.30; 95% CI, 0.13–0.70 for the dMMR population).[34][Level of evidence B1]

Sources: 34 · Level of evidence B1

These three studies demonstrate the activity and benefit of immunotherapy in the treatment of patients with advanced stage and recurrent endometrial cancer. These results may also facilitate the incorporation of such treatments into the up-front setting. More data are needed to help discern the role of immunotherapy in patients whose treatment plan would historically include radiation therapy.

Health professional · Treatment of Stage III, Stage IV, and Recurrent Endometrial Cancer / Treatment Options for Stage III, Stage IV, and Recurrent Endometrial Cancer

Clinical trials

Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

All patients with advanced disease should consider clinical trials that evaluate single-agent or combination therapy for this disease.

Studies of treatment failure patterns have found a high rate of distant metastases in the upper abdomen and in extra-abdominal sites.[35] For this reason, patients with stage III disease may be candidates for innovative clinical trials.

Sources: 35

Treatment options under clinical evaluation for stage IV endometrial cancer include the following agents:

Paclitaxel and carboplatin with or without metformin in stages III, IV, and recurrent endometrial cancer (GOG-0286B [NCT02065687]).

Sources: GOG-0286B

PI3K/mTOR inhibitor in recurrent or persistent endometrial cancer (15-079 [NCT02549989]).

Sources: 15-079

Everolimus and letrozole or hormonal therapy in recurrent or persistent endometrial cancer (GOG-3007 [NCT02228681]).

Sources: GOG-3007

Everolimus, letrozole, and metformin in advanced or recurrent endometrial cancer (2012-0543 [NCT01797523]).

Sources: 2012-0543

For patients · General Information About Endometrial Cancer

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

The prognosis and treatment options depend on the following:

Sources: prognosis

The stage of the cancer (whether it is in the endometrium only, involves the uterus wall, or has spread to other places in the body).

Sources: stage

How the cancer cells look under a microscope.

Whether the cancer cells are affected by progesterone.

Endometrial cancer can usually be cured because it is usually diagnosed early.

Sources: cured

For patients · Stages of Endometrial Cancer

Endometrial cancer may be grouped for treatment as follows:

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

For patients · Stages of Endometrial Cancer / Endometrial cancer may be grouped for treatment as follows:

Low-risk endometrial cancer

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

Grades 1 and 2 tumors are usually considered low-risk. They usually do not spread to other parts of the body.

Sources: Grades · tumors

For patients · Stages of Endometrial Cancer / Endometrial cancer may be grouped for treatment as follows:

High-risk endometrial cancer

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

Grade 3 tumors are considered high-risk. They often spread to other parts of the body. Uterine papillary serous, clear cell, and carcinosarcoma are three subtypes of endometrial cancer that are considered grade 3.

Sources: Grade · tumors · papillary serous · clear cell · carcinosarcoma · endometrial cancer

For patients · Stages of Endometrial Cancer

Endometrial cancer can recur (come back) after it has been treated.

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

The cancer may come back in the uterus, the pelvis, in lymph nodes in the abdomen, or in other parts of the body.

Sources: uterus · pelvis · lymph nodes · abdomen

For patients

Treatment Option Overview

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

There are different types of treatment for patients with endometrial cancer.

Five types of standard treatment are used:

Five types of standard treatment are used:

Surgery

Radiation therapy

Chemotherapy

Hormone therapy

Targeted therapy

New types of treatment are being tested in clinical trials.

Treatment for endometrial cancer may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up tests may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with endometrial cancer.

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

Different types of treatment are available for patients with endometrial cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: endometrial cancer · standard · clinical trials · research study · cancer

For patients · Treatment Option Overview

Five types of standard treatment are used:

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

For patients · Treatment Option Overview / Five types of standard treatment are used:

Surgery

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

Surgery (removing the cancer in an operation) is the most common treatment for endometrial cancer. The following surgical procedures may be used:

Sources: Surgery

Total hysterectomy: Surgery to remove the uterus, including the cervix. If the uterus and cervix are taken out through the vagina, the operation is called a vaginal hysterectomy. If the uterus and cervix are taken out through a large incision (cut) in the abdomen, the operation is called a total abdominal hysterectomy. If the uterus and cervix are taken out through a small incision (cut) in the abdomen using a laparoscope, the operation is called a total laparoscopic hysterectomy.

Sources: Total hysterectomy · uterus · cervix · vagina · vaginal · hysterectomy · incision · abdomen · abdominal · laparoscope

Bilateral salpingo-oophorectomy: Surgery to remove both ovaries and both fallopian tubes.

Sources: Bilateral salpingo-oophorectomy · ovaries · fallopian tubes

Radical hysterectomy: Surgery to remove the uterus, cervix, and part of the vagina. The ovaries, fallopian tubes, or nearby lymph nodes may also be removed.

Sources: Radical hysterectomy · lymph nodes

Lymph node dissection: A surgical procedure in which the lymph nodes are removed from the pelvic area and a sample of tissue is checked under a microscope for signs of cancer. This procedure is also called lymphadenectomy.

Sources: Lymph node dissection · pelvic · tissue · microscope · signs

After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given radiation therapy or hormone treatment after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

Sources: radiation therapy · hormone treatment · cells · adjuvant therapy

For patients · Treatment Option Overview / Five types of standard treatment are used:

Radiation therapy

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:

Sources: x-rays · radiation

External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: External radiation therapy

Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.

Sources: Internal radiation therapy · radioactive · seeds · catheters

The way the radiation therapy is given depends on the type and stage of the cancer being treated. External and internal radiation therapy are used to treat endometrial cancer, and may also be used as palliative therapy to relieve symptoms and improve quality of life.

Sources: stage · palliative therapy · symptoms · quality of life

For patients · Treatment Option Overview / Five types of standard treatment are used:

Chemotherapy

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy).

Sources: Chemotherapy · drugs · injected · vein · systemic chemotherapy · cerebrospinal fluid · organ · cavity · regional chemotherapy

The way the chemotherapy is given depends on the type and stage of the cancer being treated.

For patients · Treatment Option Overview / Five types of standard treatment are used:

Hormone therapy

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

Hormone therapy is a cancer treatment that removes hormones or blocks their action and stops cancer cells from growing. Hormones are substances made by glands in the body and circulated in the bloodstream. Some hormones can cause certain cancers to grow. If tests show that the cancer cells have places where hormones can attach (receptors), drugs, surgery, or radiation therapy is used to reduce the production of hormones or block them from working.

Sources: Hormone therapy · hormones · glands · receptors · drugs

For patients · Treatment Option Overview / Five types of standard treatment are used:

Targeted therapy

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do. Monoclonal antibodies, mTOR inhibitors, and signal transduction inhibitors are three types of targeted therapy used to treat endometrial cancer.

Sources: Targeted therapy · Monoclonal antibodies · mTOR inhibitors · signal transduction inhibitors

Monoclonal antibody therapy: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Bevacizumab is used to treat stage III, stage IV, and recurrent endometrial cancer.

Sources: antibodies · immune system · proteins · infusion · toxins · Bevacizumab · stage III · stage IV · recurrent

mTOR inhibitor therapy: mTOR inhibitors block a protein called mTOR, which helps control cell division. mTOR inhibitors may keep cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow. Everolimus and ridaforolimus are used to treat stage III, stage IV, and recurrent endometrial cancer.

Sources: mTOR · prevent · blood vessels · tumors · Everolimus

Signal transduction inhibitor therapy: Signal transduction inhibitors block signals that are passed from one molecule to another inside a cell. Blocking these signals may kill cancer cells. Metformin is being studied to treat stage III, stage IV, and recurrent endometrial cancer.

Sources: signals · molecule · Metformin

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

Information about clinical trials is available from the NCI website.

Sources: clinical trials · NCI website

For patients · Treatment Option Overview

Treatment for endometrial cancer may cause side effects.

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up tests may be needed.

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Stage I and Stage II Endometrial Cancer

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Low-risk endometrial cancer (grade 1 or grade 2)

Treatment of low-risk stage I endometrial cancer and stage II endometrial cancer may include the following:

Sources: stage I endometrial cancer · stage II endometrial cancer

Surgery (total hysterectomy and bilateral salpingo-oophorectomy). Lymph nodes in the pelvis and abdomen may also be removed and viewed under a microscope to check for cancer cells.

Sources: Surgery · total hysterectomy · bilateral salpingo-oophorectomy · Lymph nodes · pelvis · abdomen · microscope · cancer · cells

Surgery (total hysterectomy and bilateral salpingo-oophorectomy, with or without removal of lymph nodes in the pelvis and abdomen) followed by internal radiation therapy. In certain cases, external radiation therapy to the pelvis may be used in place of internal radiation therapy.

Sources: internal radiation therapy · external radiation therapy

Radiation therapy alone for patients who cannot have surgery.

Sources: Radiation therapy

A clinical trial of a new chemotherapy regimen.

Sources: clinical trial · chemotherapy

If cancer has spread to the cervix, a radical hysterectomy with bilateral salpingo-oophorectomy may be done.

Sources: cervix · radical hysterectomy

High-risk endometrial cancer (grade 3)

Treatment of high-risk stage I endometrial cancer and stage II endometrial cancer may include the following:

Sources: stage I endometrial cancer · stage II endometrial cancer

Surgery (radical hysterectomy and bilateral salpingo-oophorectomy). Lymph nodes in the pelvis and abdomen may also be removed and viewed under a microscope to check for cancer cells.

Sources: Surgery · radical hysterectomy · bilateral salpingo-oophorectomy · Lymph nodes · pelvis · abdomen · microscope · cancer · cells

Surgery (radical hysterectomy and bilateral salpingo-oophorectomy) followed by chemotherapy and sometimes radiation therapy.

Sources: chemotherapy · radiation therapy

A clinical trial of a new chemotherapy regimen.

Sources: clinical trial

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage III, Stage IV, and Recurrent Endometrial Cancer

Source: Endometrial Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 13, 2020. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of stage III endometrial cancer, stage IV endometrial cancer, and recurrent endometrial cancer may include the following:

Sources: stage III endometrial cancer · stage IV endometrial cancer · recurrent · endometrial cancer

Surgery (radical hysterectomy and removal of lymph nodes in the pelvis so they can be viewed under a microscope to check for cancer cells) followed by adjuvant chemotherapy and/or radiation therapy.

Sources: Surgery · radical hysterectomy · lymph nodes · pelvis · microscope · cancer · cells · adjuvant · chemotherapy · radiation therapy

Chemotherapy and internal and external radiation therapy for patients who cannot have surgery.

Sources: internal · external radiation therapy

Hormone therapy for patients who cannot have surgery or radiation therapy.

Sources: Hormone therapy

Targeted therapy with mTOR inhibitors (everolimus or ridaforolimus) or a monoclonal antibody (bevacizumab).

Sources: Targeted therapy · mTOR inhibitors · everolimus · monoclonal antibody · bevacizumab

A clinical trial of a new treatment regimen that may include combination chemotherapy, targeted therapy, such as an mTOR inhibitor (everolimus) or signal transduction inhibitor (metformin), and/or hormone therapy, for patients with advanced or recurrent endometrial cancer.

Sources: clinical trial · combination chemotherapy · signal transduction inhibitor · metformin · advanced

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus

NCT00002706 · COMPLETED · phase3

Endometrial Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage I Uterine Sarcoma, Stage II Uterine Corpus Cancer, Stage II Uterine Sarcoma

ClinicalTrials.gov record

Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus

NCT00003128 · COMPLETED · phase3

Sarcoma

ClinicalTrials.gov record

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

NCT00063999 · COMPLETED · phase3

Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA...

ClinicalTrials.gov record

Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer

NCT00411138 · UNKNOWN · phase3

Endometrial Cancer

ClinicalTrials.gov record

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

NCT01797523 · COMPLETED · phase2

Endometrial Cancer

ClinicalTrials.gov record

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

NCT02065687 · UNKNOWN · phase2, phase3

Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus...

ClinicalTrials.gov record

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

NCT02228681 · COMPLETED · phase2

Advanced, Persistent, or Recurrent Endometrial Cancer

ClinicalTrials.gov record

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

NCT02549989 · COMPLETED · phase2

Endometrial Cancer, Recurrent Endometrial Cancer

ClinicalTrials.gov record

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

NCT03517449 · COMPLETED · phase3

Endometrial Neoplasms

ClinicalTrials.gov record

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

NCT03914612 · ACTIVE NOT RECRUITING · phase3

Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial...

ClinicalTrials.gov record

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

NCT03981796 · ACTIVE NOT RECRUITING · phase3

Neoplasms

ClinicalTrials.gov record

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

NCT04269200 · ACTIVE NOT RECRUITING · phase3

Endometrial Neoplasms

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877 · ACTIVE NOT RECRUITING · phase3

Endometrial Neoplasms

ClinicalTrials.gov record

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer

NCT00112489 · COMPLETED · phase2

Sarcoma

ClinicalTrials.gov record

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

NCT00114218 · COMPLETED · phase2

Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma

ClinicalTrials.gov record

Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus

NCT00231842 · COMPLETED · phase2

Uterine Cancer

ClinicalTrials.gov record

Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer

NCT00542490 · COMPLETED · phase2

Endometrial Cancer, Papillary Serous, Clear Cell Endometrial Cancer

ClinicalTrials.gov record

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

NCT00807768 · UNKNOWN · phase3

Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome, Obesity, Stage I Uterine Corpus Cancer AJCC v7, Stage II Uterine...

ClinicalTrials.gov record

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer

NCT01168232 · COMPLETED · phase2

Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma

ClinicalTrials.gov record

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

NCT01210222 · COMPLETED · phase2

Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous...

ClinicalTrials.gov record

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

NCT01247571 · COMPLETED · phase2

Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma

ClinicalTrials.gov record

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

NCT02150213 · COMPLETED · phase2

Adrenocortical Adenoma, Endometrial Stromal Sarcomas

ClinicalTrials.gov record

Positron Emission Tomography (PET) Imaging Studies With NIS Reporter

NCT02907073 · TERMINATED · phase1, phase2

Myeloma, Endometrial Cancer

ClinicalTrials.gov record

Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer

NCT03189446 · COMPLETED · phase2

Endometrial Cancer, Papillary Serous, Clear Cell Endometrial Cancer

ClinicalTrials.gov record

A Study of Nivolumab in Selected Uterine Cancer Patients

NCT03241745 · COMPLETED · phase2

Uterine Cancer, Endometrial Carcinoma, Carcinosarcoma, Leiomyosarcoma, Undifferentiated Sarcoma, High Grade Endometrial Stromal Sarcoma, Clear Cell Carcinoma

ClinicalTrials.gov record

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

NCT03367741 · ACTIVE NOT RECRUITING · phase2

Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV...

ClinicalTrials.gov record

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

NCT03422198 · RECRUITING · phase3

Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage IA Uterine Corpus...

ClinicalTrials.gov record

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

NCT03660826 · ACTIVE NOT RECRUITING · phase2

Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage...

ClinicalTrials.gov record

ZW25 in Women With Endometrial Cancers

NCT04513665 · COMPLETED · phase2

Endometrial Cancer, Carcinosarcoma

ClinicalTrials.gov record

Disease and treatment settings

Endometrial Cancer

Disease and treatment setting

Endometrial Cancer

IMFINZI: recurrent Endometrial Cancer with DMMR stated without a specific alteration

Disease and treatment setting

1.5 Endometrial Cancer IMFINZI, in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is...

Jemperli: recurrent Endometrial Cancer

Disease and treatment setting

1.1 Endometrial Cancer JEMPERLI, in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC).

Jemperli: recurrent Endometrial Cancer with DMMR stated without a specific alteration after prior therapy

Disease and treatment setting

Adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.

KEYTRUDA QLEX: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration after prior therapy

Disease and treatment setting

KEYTRUDA QLEX, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have...

KEYTRUDA QLEX: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration, DMMR stated without a specific alteration after prior therapy

Disease and treatment setting

KEYTRUDA QLEX, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic...

KEYTRUDA QLEX: recurrent Endometrial Carcinoma

Disease and treatment setting

1.15 Endometrial Carcinoma KEYTRUDA QLEX, in combination with carboplatin and paclitaxel, followed by KEYTRUDA QLEX as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial...

KEYTRUDA: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration after prior therapy

Disease and treatment setting

KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have...

Keytruda: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration, DMMR stated without a specific alteration after prior therapy

Disease and treatment setting

In combination with lenvatinib for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation

KEYTRUDA: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration, DMMR stated without a specific alteration after prior therapy

Disease and treatment setting

KEYTRUDA, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic...

KEYTRUDA: recurrent Endometrial Carcinoma

Disease and treatment setting

1.17 Endometrial Carcinoma KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.

Lenvima: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration after prior therapy

Disease and treatment setting

1.4 Endometrial Carcinoma LENVIMA, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high...

Lenvima: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration, DMMR stated without a specific alteration after prior therapy

Disease and treatment setting

In combination with pembrolizumab for advanced endometrial carcinoma not MSI-H or dMMR, with progression following systemic therapy and not candidates for curative surgery or radiation

Stage I Endometrial Cancer

Disease and treatment setting

Treatment of Stage I and Stage II Endometrial Cancer

Stage III recurrent Endometrial Cancer

Disease and treatment setting

Treatment of Stage III, Stage IV, and Recurrent Endometrial Cancer

Drug labels

IC-Green

Label date 2026-01-30

• Fluorescence imaging of vessels (micro- and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general...

DailyMed label

Jemperli

Label date 2025-09-02

JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Endometrial Cancer • in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult patients with primary...

DailyMed label

medroxyprogesterone acetate

Label date 2026-05-21

INDICATIONS AND USAGE Medroxyprogesterone acetate tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine...

DailyMed label

PROGESTERONE

Label date 2022-10-05

INDICATIONS AND USAGE This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer.

DailyMed label

Provera

Label date 2026-06-29

INDICATIONS AND USAGE PROVERA tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also...

DailyMed label

Zyogreen

Label date 2026-07-16

ZYOGREEN is an optical imaging agent indicated for: Fluorescence imaging of vessels (micro- and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro-...

DailyMed label